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Abstract: Genomic structural changes, such as gene Copy Number Variations (CNVs) are extremely abundant in the hu-
man genome. An enormous effort is currently ongoing to recognize and catalogue human CNVs and their associations 
with abnormal phenotypic outcomes. Recently, several reports related neuropsychiatric diseases (i.e. autism spectrum dis-
orders, schizophrenia, mental retardation, behavioral problems, epilepsy) with specific CNV. Moreover, for some condi-
tions, both the deletion and duplication of the same genomic segment are related to the phenotype. Syndromes associated 
with CNVs (microdeletion and microduplication) have long been known to display specific neurobehavioral traits. It is 
important to note that not every gene is susceptible to gene dosage changes and there are only a few dosage sensitive 
genes. Smith-Magenis (SMS) and Potocki-Lupski (PTLS) syndromes are associated with a reciprocal microdeletion and 
microduplication within chromosome 17p11.2. in humans. The dosage sensitive gene responsible for most phenotypes in 
SMS has been identified: the Retinoic Acid Induced 1 (RAI1). Studies on mouse models and humans suggest that RAI1 is 
likely the dosage sensitive gene responsible for clinical features in PTLS. In addition, the human RAI1 gene has been im-
plicated in several neurobehavioral traits as spinocerebellar ataxia (SCA2), schizophrenia and non syndromic autism. In 
this review we discuss the evidence of RAI1 as a dosage sensitive gene, its relationship with different neurobehavioral 
traits, gene structure and mutations, and what is known about its molecular and cellular function, as a first step in the elu-
cidation of the mechanisms that relate dosage sensitive genes with abnormal neurobehavioral outcomes.  
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GENOMIC STRUCTURAL CHANGES AND NEURO-
PSYCHIATRIC TRAITS  
  Genomic structural changes, such as gene Copy Number 
Variations (CNVs) are extremely abundant in the human 
genome. Approximately 14,400 CNV loci larger than 1 kb 
were identified to date (http://projects.tcag.ca/variation/) [1]. 
In a recent article the impressive amount of more than 1,000 
CNV/individual human genome ranging from 443 bp to 1.28 
megabases (Mb), with a median size of 2.9 kb was reported 
[2]. On the other hand, an enormous effort is currently ongo-
ing to recognize and catalogue human CNVs associated with 
abnormal phenotypic outcomes [3-7]. Some conditions af-
fecting the central nervous system, such as schizophrenia, 
mental retardation (MR) and autism spectrum disorder 
(ASD) were shown recently to be associated with both the 
deletion and the duplication of the same genomic segment 
[8-13]. There is a great level of complexity between the 
presence of CNV and the resulting phenotypes that is not 
only a direct consequence of specific altered gene dosage. 
Analyses of the genome-wide functional impact of these 
structural variants showed that copy number changes not   
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only cause alterations in expression levels of genes within 
CNVs but also influence the expression of genes in their 
vicinity [14, 15]. Moreover, a recent study clearly demon-
strates that the presence of structural changes associated with 
CNV is enough to cause a phenotype independent of gene 
dosage [16].  
  Genomic disorders are the clinical manifestation of 
pathological CNV, they are frequent conditions (~ 1 per 
1,000 births) and often sporadic resulting from de novo rear-
rangements [17]. In a subset of such conditions the rear-
rangements comprise multiple unrelated contiguous genes 
that are physically linked and thus have been referred to as 
Contiguous Gene Syndromes (CGS). An increasing number 
of CGS are being described each of them presenting a com-
plex and specific phenotype. The beauty of these CGS is that 
there are specific phenotypes associated with certain ge-
nomic regions, thus making the detection of the genes in-
volved in certain pathways easy. Although the segmental 
aneuploidy usually involves several genes, only a small sub-
set of them conveys phenotypes as a function of copy num-
ber alteration. These particular genes are referred as “dosage 
sensitive genes”. However, the question of what makes a 
gene or its product a “dosage sensitive gene” remains to be 
elucidated. 
  Smith-Magenis (SMS, OMIM# 182290) and Potocki-
Lupski (PTLS, OMIM# 610883) syndromes are two exam-
ples of CGS that are associated with a microdeletion and a 608    Current Genomics, 2010, Vol. 11, No. 8  Carmona-Mora and Walz 
microduplication respectively within chromosome 17 band 
p11.2. SMS was first described in 1986, and has a birth 
prevalence estimated at 1/15,000-1/25,000 [18-20]. The 
clinical phenotype includes craniofacial abnormalities, 
brachydactyly, self-injurious behavior, sleep abnormalities 
and mental retardation. Less commonly reported is cleft pal-
ate, congenital heart defects, seizures, hearing impairment 
and urinary tract anomalies. Molecular studies revealed a 
common deleted region of ~4 Mb in the majority of SMS 
patients (>70-80%) [21]. Unusual sized deletions (smaller or 
larger) were observed in 20–25% of patients. By examining 
the breakpoints in unusual sized deletions, the SMS critical 
region was redefined to a ~950 kb interval, in which fifteen 
genes and eight predicted genes were present [22] (Table 1). 
PTLS was first described in 2000 [23] and is associated with 
the reciprocal duplication of the genomic interval deleted in 
SMS. The clinical presentation of PTLS includes mental 
retardation, autistic features, hyperactivity, developmental 
delay and dysmorphic features. In addition, PTLS patients 
present hypotonia, poor feeding and difficulty to thrive in 
infancy, oral-pharyngeal dysphasia, obstructive and central 
sleep apnea, structural cardiovascular abnormalities, electro-
encephalogram (EEG) abnormalities, behavioral abnormali-
ties, and hypermetropia [24-26] (Table 1). 
RAI1 IS THE DOSAGE SENSITIVE GENE MOSTLY 
RESPONSIBLE FOR THE SMS AND PTLS CLINICAL 
PRESENTATION 
  As mentioned above, only a few genes do appear to be 
clearly haploinsufficient, such that hemizygotes exhibit a 
recognizable phenotype. Point mutations (nonsense and 
frameshift as well as missense alleles) in the Retinoic Acid 
Induced 1 gene (RAI1) were identified in patients with clini-
cal presentation of SMS but no molecular deletion found by 
FISH [30-33] (Tables 1 and 2), suggesting that RAI1 is the 
dosage sensitive gene causative of SMS. In specific, there 
are two cases of patients with SMS that carry missense muta-
tions that alter amino acids within a highly conserved region 
of the gene (A4685G and G5423A). Both patients have a 
wide spectrum of neurobehavioral phenotypes, including 
sleep disturbance, self-injurious behaviors, mental retarda-
tion and developmental delay. This supports the fact that 
RAI1 is a protein directly involved in these specific neuro-
behavioral phenotypes, since the point mutations mentioned 
above generate a full length protein with only the change of 
one single amino acid, with stability similar to the wild type 
protein [34]. 
  In addition, a recent report showed a patient with PTLS 
phenotype having a duplication of a very small region that 
only contains the RAI1 gene [29]. This is consistent with the 
notion of RAI1 as the dosage sensitive gene within this ge-
nomic region (Table 1). 
 Additional  support to the idea that RAI1 is the dosage 
sensitive gene within this interval comes from studies in 
mouse models. Human chromosome 17p11.2 is syntenic to 
the 32-34 cM region of murine chromosome 11. The number 
and order of the genes are highly conserved [36-38]. By 
chromosome engineering, a strategy developed to introduce 
defined chromosomal rearrangements into the mouse ge-
nome to delineate gene haploinsufficiency effects (haploid 
genetics) [39-43], a deletion and reciprocal duplication in the 
mouse chromosome region syntenic to the SMS critical in-
Table 1.  Key Neurobehavioral Features Found in SMS and PTLS Patients 
SMS  PTLS 
Neurobehavioral features 
% in common deletion  % in RAI1 mutations  % in common duplication  % in small duplications 
Variable mental retardation or 
cognitive impairment  100 100  100  100 
Motor and speech delay  >90  70  100  100 
Sleep disturbance  90  100  66.6  75 
Infantile hypotonia >90  61 88.8  75 
Overt seizures  11–30  16.6  NR  NR 
EEG abnormalities 49  NR  66.6-70  5.8 
Attention seeking  80–100  100  NR  NR 
Onychotillomania 25–85  100 NR  NR 
Polyembolokoilamania 25–85  80  NR  NR 
Hand biting/self-biting  80  60  NR  NR 
Self-injurious behaviors  70–90  100  NR  NR 
Self-hugging/hand wringing  50–80  100  NR  NR 
Head banging/face slapping  70  90  NR  NR 
Self-picking 54  100  NR  NR 
Hyperactive 80  100  >70  66.6 
Autistic features  NR  NR  87.5  66.6 
A comparison between the phenotypes present in patients with the genomic rearrangements and point mutations of RAI1 gene is shown. For SMS, the clinical features are presented 
in the percentage of patients carrying either the common 17p11.2 deletion (~3.7 Mb) or a mutation in RAI1 gene. The percentages of features in PTLS are represented for patients 
that harbor the common 17p11.2 duplication (~3.7 Mb) or small duplications (<1 Mb). (NR: not reported) [25, 27-29]. A Dosage Sensitive Gene Related to Neurobehavioral Alterations  Current Genomics, 2010, Vol. 11, No. 8    609 
terval were generated  [44]. The mouse model for SMS, 
Df(11)17/+ or Del, carries a ~1.7 Mb deletion and presents 
craniofacial abnormalities, seizures, obesity, alterations in 
circadian rhythm and hypoactivity, decreased anxiety in the 
plus maze test, social interaction differences in the tube test 
and the social novelty test recapitulating most of the pheno-
types observed in human patients [15, 44-47]. The mouse 
model for PTLS syndrome, Dp(11)17/+ or Dup, carries a 
duplication of a region of ~1.7 Mb and are significantly 
leaner than wild type mice, hyperactive and exhibit impaired 
contextual fear conditioning, they display increased anxiety 
behavior in the plus maze test and increased dominance in 
the tube test. Abnormal sociability and preference for social 
novelty was also observed [15, 44, 45]. 
  Interestingly enough, most of the phenotypes present in 
Dup mice were rescued in the Dup/Rai1
- compound het-
erozygote (obtained by mating Dup mice with Rai1
+/- mice, a 
model with Rai1 haploinsufficiency) where the gene dosage 
of Rai1 was 2n despite the presence of 3 copies of the other 
23 genes in the region; being the first indication of Rai1 as 
the dosage sensitive gene responsible the PTLS syndrome 
[50]. Consistent with this, there have been reports of mouse 
models with underexpression of Rai1 [48] and overexpres-
sion of Rai1 [51] that presented several of the expected phe-
notypes. For the last one, analyses in both hemizygous and 
homozygous transgenic mice revealed a dosage-dependent 
exacerbation of the phenotype, which included growth retar-
dation, increased anxiety and hyperactivity [51]. A summary 
can be seen in Table 3.  
 Utilizing  the  Del and Dup mouse models, the levels of 
expression of Rai1 and the other genes within this specific 
genomic rearrangement were studied. Genome-wide expres-
sion levels in four organs (cerebellum, heart, kidney and 
testis) from adult male mice (at least three animals of Dup, 
Del, Dup/Del and wild type mice) showed a positive correla-
tion between gene dosage and expression levels [15, 16]. 
The transcripts within the rearranged interval are expressed 
on average 0.66 (SD=0.15) fold less in the Del (one copy) 
and 1.38 (SD=0.29) fold more in Dup animals (three copies). 
They were, however, unchanged in Del/Dup mice (1.02 
(SD=0.16) fold more, two copies in cis) compared to normal 
controls (two copies in trans) [16]. This clearly showed that 
Rai1 gene copy number is correlated with levels of expres-
sion of the gene, and suggests that the protein levels are 
modified concomitant with gene dosage. Interestingly 
enough, most of the genes within this genomic interval be-
have in the same way, suggesting that is not the levels of  
 
Table 2.  RAI1 Gene Variations Related with Neurobehavioral Phenotypes 
Mutation  Exon  Resultant protein 
Mental 
retardation 
Sleep  
disturbance 
Speech 
delay 
Motor 
delay 
Self  
injurious 
behavior 
Develop-
mental delay 
Hypotonia 
32253del19 3  Missincorporation of 60 
aa 
+ +  +  +  +  NR  + 
351119delC 3  Missincorporation of 65 
aa 
+ +  NR  NR  +  NR  NR 
301449delC 3  Missincorporation of 34 
aa 
+ +  NR  +  +  NR  + 
302773del29 3  Missincorporation of 8 
aa 
+ +  +  NR  +  NR  NR 
31C2878T 3  R960X  +  +  NR  NR  +  NR  NR 
313103insC 3  Missincorporation of 30 
aa 
+ +  NR  NR  +  NR  NR 
333103delC 3  Missincorporation of 28 
aa 
+ +  +  NR  +  NR  NR 
323801delC 3  Missincorporation of 46 
aa 
+ +  NR  +  +  NR  NR 
354649delC 3  Missincorporation of 36 
aa 
+ +  NR  NR  +  NR  NR 
32A4685G 3  Q1562R  +  +  +  +  +  NR  + 
354933delGCCG 3 Missincorporation of 35 
aa 
+ +  NR  NR  +  +  NR 
305265delC 3  Missincorporation of 74 
aa 
+ +  NR  NR  +  NR  NR 
32G5423A 3  S1808N  +  +  + NR  +  NR  + 
33A3634G 3  S1212G               
33(PolyQ)18 3  (PolyQ)18 +  +  +    +  +  + 
The mutations found in SMS patients are listed with their position in the cDNA, the protein that they generate and the neurobehavioral phenotypes associated with each mutation (+ 
means the presence of the characteristic, NR: not reported) [30-33, 35]. 610    Current Genomics, 2010, Vol. 11, No. 8  Carmona-Mora and Walz 
expression that make the difference between Rai1 and the 
other 23 genes in the region.  
MOLECULAR ASPECTS OF RAI1 
 RAI1  lies in the middle of the Smith-Magenis critical 
region, spanning over 120 kb. It consists of six exons, being 
the third exon the one that contains more than 90% of the 
coding region.  
  As is shown in Fig. (1), there are several regions recog-
nizable in RAI1 protein structure. A polymorphic CAG re-
peat encoding for a polyglutamine tract is present in the N-
terminus of the RAI1 protein. Two polyserine tracts, each 
located at the N and C-terminal regions. The polyserine sig-
nal is similar to the one present in the DRPLA gene and the 
Drosophila hairless gene, both proteins involved in neuronal 
development [53, 54]. RAI1 has two putative bipartite nu-
clear localization signals (NLSs) in silico predicted. It also 
possesses a zinc finger like plant homeo domain (PHD) in 
the C-terminus, which is present in the trithorax family of 
chromatin remodeling transcriptional regulators [30, 31]. 
The isoform 1 of RAI1 corresponds to the canonical se-
quence, and it is found in high levels mainly in brain and 
heart [55]. There are other three isoforms produced by alter- 
native splicing which are described in the online database 
Universal Protein Resource (www.UniProt.org). These iso- 
forms differ from the canonical one by the change or lack of 
several residues; the schematic representations of these struc- 
tures are represented in Fig. (1). Isoform 2 is the most simi- 
lar to the canonical, with a length of 1862 amino acids and 
domain conservation [53]. In the isoform 3 (1640 amino ac- 
ids) the second polyserine tract and PHD domain are missing 
[56]. Isoform 4 is the shortest, containing only the first half 
of RAI1 protein (966 amino acids) [57] not encompassing 
NLSs and being comparable to the truncated protein found in 
some SMS patients. This short isoform has been found in 
muscle, while the other proteins have been described from 
brain tissue. In addition to the isoforms 2, 3 and 4 of RAI1, 
the online database of eukaryotic genomes, Ensembl project 
(www.ensembl.org) reports other two transcripts 
(ENST00000395776 and ENST00000428973), also gener- 
ated by alternative splicing and both produce the same RAI1 
protein of 1993 amino acids (ENSP00000379122). This pro- 
tein shares a 100% homology with the isoform 1 until the 
residue 1855. It is important to note that in the same data-
base, several transcripts of RAI1 were found, and these are 
consistent with the records of the other variants reported in 
the databases of UniProt and UCSC Genome Browser 
(http://genome.ucsc.edu/).  
  Besides the domains described above for the protein, 
there are several post-translational modifications (PTM) sites 
found in RAI1, both in silico and experimentally. Some ex-
perimental evidence of PTM present in the RAI1 protein 
comes from in vitro studies where the isoform 1 and five 
RAI1 mutated forms of the protein (RAI1-HA 2687delC, 
RAI1-HA 3103delC, RAI1 R960X, RAI1-HA Q1562R, and 
RAI1-HA S1808N, four of them associated with SMS clini-
cal phenotype) were studied. In this report all proteins pre-
sented a higher molecular weight than expected when run in 
an SDS-PAGE gel analysis. Moreover, the PTM were be 
mapped to the N-terminal of RAI1 [34]. Through the analy-
sis of RAI1 sequence with NetGlycate 1.0, NetOGlyc 3.1 
and YinOYang 1.2 servers [58-60], we found several pre-
dicted glycation sites homogenously located within the pro-
tein sequence and more interestingly, there are several O-
glycosylation sites with high score, most of them mapping in 
the first amino-terminal half of RAI1. There are also O-
linked  -N-acetylglucosamine (O-GlcNac) predicted sites 
with high score, which are present in many transcription fac-
tors and neuronal proteins; this modification participates in 
transcription, translation, proteasomal degradation and apop-
tosis among others and is directly involved in the regulation 
of neuronal development and synaptic transmission [61]. 
  Phosphorylation is a well established PTM, implicated in 
protein regulation in a variety of cellular processes. We ran 
Table 3.  Rai1 CNV is Sufficient to Cause Most of the Phenotypes of SMS and PTLS also in Mice 
Mouse model 
Phenotype  
Del  Rai1
+/-  Dup  Dup/Rai1
-  Tg Rai1 
Overt seizures  Present (20%)  Subtle  No present  No present  No present 
EEG Abnormal  Abnormal  Normal  ND  ND 
Locomotor  activity  Hypoactive  Abnormal  Hyperactive Hyperactive Hyperactive 
Anxiety Decreased  Abnormal  Increased  Normal  Increased 
Learning and memory  Normal  Normal  Impaired  Normal  ND 
Social novelty recognition  Abnormal ND  Impaired  ND Abnormal 
Dominance like behavior  Decreased  ND  Increased  ND  Increased 
Reference  [16, 44, 45]  [48-50]   [15, 16, 44, 45, 50]  [50]  [51, 52] 
Summary of the neurobehavioral phenotypes observed in existing mouse models for SMS and PTLS. Del and Rai1
+/- mice carry one gene copy of Rai1, Dup model carries three 
copies, Tg Rai1 has several copies and Dup/Rai1
- has two copies or Rai1 gene. (N/D: not determined).  A Dosage Sensitive Gene Related to Neurobehavioral Alterations  Current Genomics, 2010, Vol. 11, No. 8    611 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Structure of RAI1. By in silico analyses, several domains have been found for RAI1: a polyglutamine tract at the N-terminal of the 
protein, two polyserine domains, a PHD domain at the C-terminal of RAI1 and two putative nuclear localization signals (NLS). RAI1 protein 
structure is schematically represented, and the domains described are showed with their localization in the amino acidic sequence. By the 
evaluation of the wild type and mutant proteins associated to SMS, two main domains were found: the N-terminal half of RAI1 is responsible 
for the transactivational activity and C-terminal half beginning in residue 1038 is responsible for nuclear localization [34]. The RAI1 PTMs 
found are depicted with black figures while the putative sites are represented by white figures. The phosphorylation sites (1Thr and 13Ser) 
found in HeLa cells are represented with black circles. The reported acetylation site is depicted with a black diamond. The putative SUMOy-
lation site with the highest score is represented with a white triangle.  
Below, the other four isoforms described for human RAI1 are represented. These isoforms differ from the canonical one by the change of 
several residues (depicted in slanted rectangles) and also by some fragments missed (depicted by discontinued lines). Isoform 2 is the most 
similar to the canonical, while in isoform 3 are missing the second polyserine tract and PHD domain. Isoform 4 is the shortest containing only 
the first half of RAI1 protein, not encompassing NLSs and being comparable to the truncated proteins found in some SMS patients. The long-
est variant of RAI1 (ENSP00000379122) is a protein reported by the online database of eukaryotic genomes, Ensembl, which has a length of 
1993 amino acids and has complete homology with the isoform 1 until amino acid 1855.  
an  in silico analysis of putative phosphorylation sites for 
RAI1 (NetPhos 2.0 Server [62]), and found the number of 
putative phosphorylable amino acid/total as follows: 
Ser128/217, Thr36/99, and Tyr13/39, indicating the exis-
tence of several possible phosphorylation sites. Consistent 
with these predictions, in recent studies to assess the global 
in vivo phosphoproteome one threonine (Thr1186) and thir-
teen serines (Ser568, 571, 574, 687, 1107, 1108, 1110, 1121, 
1122, 1352, 1358, 1374 and 1616) were identified in a phos-
phorylated state in the RAI1 protein, and three of them 
(Ser568, Ser571 and Ser574) were regulated upon EGF 
stimulation in HeLa cells [63-66]. Interestingly, most of 
these sites are consensus for CK1, GSK3, NEK6 and ERK 
kinases.  
  Lysine acetylation is a reversible PTM, which neutralizes 
the positive charge of this amino acid, changing protein 
function. This PTM is very important in the regulation of 
gene expression through the modification of histone proteins. 
Site-specific acetylation of a growing number of non-histone 
proteins has been shown to regulate their activity, localiza-612    Current Genomics, 2010, Vol. 11, No. 8  Carmona-Mora and Walz 
tion, specific interactions as well as stability/degradation, 
therefore controlling a variety of cellular processes, such as 
transcription, proliferation, apoptosis and differentiation 
[67]. Interestingly, in another large scale analysis [68] an 
acetylation modification was reported for RAI1 at the pep-
tide KGLEQGGKASDGISK in the Lysine 774 (underlined), 
which also presented a high accessibility rate in the 3D struc-
ture. 
  SUMOylation (Small Ubiquitin-like Modifier proteins) is 
a post-translational modification involved in various cellular 
processes, such as nuclear-cytosolic transport, transcriptional 
regulation, apoptosis, protein stability, response to stress, 
and progression through the cell cycle [69, 70]. In silico 
analysis (SUMOsp 2.0 [71]) of the RAI1 protein sequence 
gave seven putative SUMOylation sites of the TypeI: -K-
X-E, in Lys549, 811, 819, 988, 1328, 1425 and 1500 (being 
Lys819 the most probable one). Therefore, the prediction of 
several sites for PTM within RAI1 sequence and the differ-
ence between the obtained vs. expected molecular weight of 
the protein, are consistent with a PTM in the N-terminal do-
main of RAI1 (Fig. (1)). 
RAI1 MOLECULAR AND CELLULAR FUNCTION 
  Little is known about the cellular and developmental role 
of RAI1. The first study was made in a mouse embryonic 
carcinoma cell line (P19) where the expression of GT1, a 
splice variant of Rai1 was markedly up-regulated after the 
treatment with retinoic acid for inducing neuronal differen-
tiation [72].  
  Initially it was suggested, based in bioinformatic analyses 
that RAI1 could function as a transcriptional regulator [30, 
31]. RAI1 and TCF20, a transcriptional cofactor, share a 
homology of 50% at the amino acid level, and both genes 
have a similar structure. Furthermore, the presence of the 
polyglutamine stretch at the N-terminal of RAI1 is coinci-
dent with many transcription factors containing polyglu-
tamine activation domains and it has been shown that these 
stretches can modulate the transcription activation [73]. Con-
sistent with this speculation, it was reported that mouse Rai1 
has transactivational activity in HeLa cells but in moderate 
levels [48]. Considering it had milder activity than classical 
transcription factors, this can indicate that Rai1 might not act 
alone but may be part of a complex that regulates transcrip-
tion. In 2010, an independent study showed that mouse Rai1 
had much stronger transactivation activity in Neuro-2a cells 
(a neuronal derived cell line) than in HeLa cells [34]. These 
results suggest specificity in the transcription machinery that 
RAI1 could be part of and further indicate the importance of 
its role in neuronal derived tissues, since RAI1 is a dosage 
sensitive gene involved in neurobehavioral phenotypes. 
Moreover, it was also demonstrated that human RAI1 has 
transcription factor activity [34] and is able to localize to the 
nucleus. Intriguingly, the two missense mutations (RAI1 
Q1562R and RAI1 S1808N) were shown to localize to the 
nucleus and activate transcription of a reporter gene in the 
same magnitude than the wild type protein, strongly suggest-
ing that these mutations are involved in other functions yet 
unknown for RAI1. The analysis of the mutations RAI1-HA 
2687delC,  RAI1-HA 3103delC and RAI1 R960X showed 
that they generated a truncated polypeptide with cytoplas-
matic localization and higher transcription factor activity 
than the wild type protein. In addition, two different C-
terminal halves of RAI1 protein (1038 aa-end and 1229 aa-
end) were able to localize into the nucleus but had no trans-
activation activity. Taking all this into consideration plus the 
mouse protein studies previously reported [48], two func-
tional domains were assigned to each half of RAI1: the N-
terminal that contains transactivational activity and the C-
terminal half of RAI1 responsible for the correct subcellular 
localization of the protein. In a normal situation the two 
functional domains of the protein are together. This suggests 
that the pathogenic outcome of some of the mutated forms 
may be explained by the dissociation of these two domains. 
However, in this context it is intriguing, and needs further 
study, the contribution of the different RAI1 isoforms to the 
final phenotype. 
  Therefore, it is clear that RAI1 is regulating gene expres-
sion and there are new data from cells and mice regarding to 
this aspect of the protein. A genome-wide gene expression 
study made in HEK293T (human embryonic kidney cells) 
with a 50% knockdown of RAI1 generated by siRNA was 
performed using microarrays [74]. The top dysregulated 
genes found in these RAI1 haploinsufficient cells are in-
volved in neuronal differentiation, circadian activity and 
behavior; besides growth signaling, insulin sensitivity, gene 
expression, cell-cycle regulation, lipid biosynthesis, fat mo-
bilization and skeletal, cardiovascular and renal develop-
ment. The top candidate genes found upregulated due to 
RAI1 haploinsufficiency are ZIC1, PSEN2, RXRB, CLN8 and 
SCN12A being involved in neurogenesis, mental retardation, 
sensory transmission, nociceptive behavior, epilepsy and 
neurological function. Amongst the top candidate genes that 
are downregulated there are NF1, MLL and NR1D2, which 
are associated to schizophrenia, neurofibromatosis type I and 
circadian activity [74]. 
  Recently in the mouse model for Rai1 haploinsuffi-
ciency, Rai1
+/-, several genes were reported to be dysregu-
lated in the hypothalamus [75]. These genes include Slc6a12 
and Slc38a5, which are related to traits like epilepsy, anxiety 
disorder, mental retardation, whose expression is downregu-
lated as a consequence of the haploinsufficiency of Rai1. 
Furthermore, it was found that human RAI1 isoform 1 di-
rectly regulates the expression of BDNF (brain-derived neu-
rotrophic factor) [75] which is a neurotrophin that regulates 
neuronal survival, differentiation and growth during brain 
development, among others. The expression of this gene is 
known to be reduced in patients with Alzheimer, Parkinson 
and Huntington diseases [76]. Additionally, BNDF has been 
reported to be associated with obesity and hyperphagia [77, 
78].  
  Moreover, altered gene expression was found for many 
genes in a hippocampus expression profile of the Dup mouse 
model for PTLS [15]. In this study the transcript of Ataxin 2, 
a protein mutated in spinocerebellar ataxia type 2 (SCA2), 
had a fold change of 1.24 by microarray analysis; certainly 
suggesting a link between its expression and the overexpres-
sion of Rai1.  
  Altogether, the studies showing that CNV of RAI1 causes 
dysregulation of many genes involved in many different cel-
lular processes, suggest that RAI1 functions through specific A Dosage Sensitive Gene Related to Neurobehavioral Alterations  Current Genomics, 2010, Vol. 11, No. 8    613 
pathways involved in the regulation of various biological 
processes, and when disrupted result in the phenotypic ef-
fects observed in SMS, PTLS and other neurobehavioral 
traits.  
RAI1 HAS BEEN IMPLICATED IN SEVERAL NEU-
ROBEHAVIORAL TRAITS 
  As mentioned before, the haploinsufficiency of RAI1 
causes SMS meanwhile the duplication of a small region 
containing this gene is able to cause PTLS. Besides the 
strong association of RAI1 with these two genomic disor-
ders, this protein has been reported to be related with other 
neurobehavioral traits.  
  At the N-terminus of the RAI1 protein there is a poly-
morphic CAG repeat, which length is associated with the age 
of onset of spinocerebellar ataxia type 2 [79] and the re-
sponse to neuroleptic medication in schizophrenia [80]. In 
addition, RAI1 has been shown to be associated with non 
syndromic autism [81].  
  Spinocerebellar ataxia type 2 (SCA2) is an autosomal 
dominant disease caused by the increment of a CAG repeat 
tract in ataxin-2 gene, generating an expanded polyglutamine 
tract in this protein. A study of the association between CAG 
repeat length and age at onset variability in SCA2 [79] in 
more than 100 patients found that RAI1 locus contributes to 
4.1% of the variance in SCA2 age at onset, after the effect 
caused by the expanded ataxin-2 protein. Therefore, this is 
the only association reporting RAI1 as a contributor in a neu-
rodegenerative disorder, and due to a larger polyglutamine 
tract in RAI1 protein, which ranges from 10 to 16 glutamines 
in the normal population [33].  
  It was reported that a CAG repeat polymorphism in RAI1 
is associated with both the severity of the phenotype and the 
response to medication in schizophrenic patients [80]. Com-
pared to non-responders, schizophrenic subjects responding 
to neuroleptic medication are characterized by a later age of 
onset and a better long-term outcome. The group responding 
to medication carried a significantly shorter CAG repeat size 
compared to control groups.  
  It is remarkable to mention that CAG repeat polymor-
phism of RAI1 have not been found to be causative of the 
SMS phenotype; and the length of this CAG repeat has not 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). RAI1 changes associated with neurobehavioral phenotypes. The traits that have been found related to RAI1 CNVs, mutations or 
sequence changes are summarized. There are phenotypes that are associated with only one copy of RAI1 gene (SMS). Many of these pheno-
types are also related to carrying two copies of the gene, but one allele with mutations (SMS caused by frameshifts, nonsense or missense 
mutations) 
(a). Harboring two copies of RAI1 gene but with polymorphic CAG repeats influence other neurobehavioral traits
 (b). The alteration 
of RAI1 dosage to three copies causes specific phenotypes of PTLS as well as features that overlap with some clinical characteristics of SMS. 614    Current Genomics, 2010, Vol. 11, No. 8  Carmona-Mora and Walz 
been analyzed in PTLS patients. The most common polyglu-
tamine tracts in normal and SMS patients are 13-14 Gln. The 
comparison of phenotypes in SMS deletion patients with 
different number of CAG repeats did not show any associa-
tion between CAG repeat length and the severity of SMS 
phenotype [33]. Recently, in a study with a group of patients 
with non-complex-autism, RAI1 was found to be one of the 
novel autism candidate genes within the autism-associated 
CNVs regions [81]. In this study, RAI1 was the top most 
significant gene identified in the analysis of 173 non-
overlapping CNV regions.  
  All of these data indicate that RAI1 is participating in 
different aspects of behavior regulation. In Fig. (2) are sum-
marized the neurobehavioral traits related with RAI1 varia-
tions. In summary, there is plenty of evidence indicating that 
RAI1 is the dosage sensitive gene responsible for most of the 
phenotypes of SMS and PTLS syndromes, including several 
neurobehavioral traits.  
  It is also possible to suggest that RAI1 might have a role 
modulating some aspects of neuron function or differentia-
tion since in addition to its contribution in both SMS and 
PTLS phenotypic outcome, it is highly expressed in neurons, 
its expression is influenced by retinoic acid and has polyglu-
tamine polymorphisms that have been found to be associated 
with schizophrenia and spinocerebellar ataxia type 2. Taking 
into consideration the information known to date from stud-
ies in vitro, it can be hypothesized that at the cellular level 
the cause of the resulting phenotypes related to alterations in 
RAI1 can be due to (either or together) an abnormal translo-
cation of the protein, reduced transactivational activity or 
inability of interaction with other proteins and/or DNA due 
to changes in a specific motif or to modifications in the 3D 
structure. 
  However, further studies are necessary with RAI1 and 
generally with all the other dosage sensitive genes known up 
to date in order to answer the main question that remains 
unanswered: what makes a gene, or its product, a dosage 
sensitive one? 
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